Barclays’s Protalix BioTherapeutics PLX Stock Holding History

Barclays’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.2K	Sell	14,822 -98,027	-87%	-$243K	﹤0.01%	4454
2025 Q4	$203K	Buy	112,849 +11,051	+11%	+$22.6K	﹤0.01%	4299
2025 Q3	$226K	Sell	101,798 -25,165	-20%	-$41K	﹤0.01%	4244
2025 Q2	$188K	Buy	126,963 +102,653	+422%	+$210K	﹤0.01%	4323
2025 Q1	$62.2K	Sell	24,310 -10,013	-29%	-$23.9K	﹤0.01%	4563
2024 Q4	$64.5K	Hold	34,323	–	–	﹤0.01%	4699
2024 Q3	$35K	Sell	34,323 -1,104	-3%	-$1.16K	﹤0.01%	4815
2024 Q2	$41.5K	Sell	35,427 -47,007	-57%	-$55.5K	﹤0.01%	4280
2024 Q1	$104K	Sell	82,434 -43,268	-34%	-$64.6K	﹤0.01%	4418
2023 Q4	$224K	Buy	125,702 +79,191	+170%	+$123K	﹤0.01%	4366
2023 Q3	$77.2K	Buy	46,511 +33,281	+252%	+$59.7K	﹤0.01%	3685
2023 Q2	$26.5K	Buy	13,230 +11,230	+562%	+$26.8K	﹤0.01%	4077
2023 Q1	$4.2K	Hold	2,000	–	–	﹤0.01%	4845
2022 Q4	$2.74K	Hold	2,000	–	–	﹤0.01%	5062
2022 Q3	$2K	Hold	2,000	–	–	﹤0.01%	4637
2022 Q2	$2K	Hold	2,000	–	–	﹤0.01%	4887
2022 Q1	$2K	Buy	+2,000	New	+$1.83K	﹤0.01%	4790
2019 Q4	–	Sell	-2,003	Closed	-$4K	–	6707
2019 Q3	$4K	Buy	2,003 +3	+0.2%	+$9	﹤0.01%	6486
2019 Q2	$9K	Hold	2,000	–	–	﹤0.01%	6582
2019 Q1	$9K	Hold	2,000	–	–	﹤0.01%	6588
2018 Q4	$6K	Hold	2,000	–	–	﹤0.01%	6386
2018 Q3	$15K	Hold	2,000	–	–	﹤0.01%	6549
2018 Q2	$9K	Hold	2,000	–	–	﹤0.01%	6575
2018 Q1	$11K	Hold	2,000	–	–	﹤0.01%	6638
2017 Q4	$13K	Hold	2,000	–	–	﹤0.01%	6452
2017 Q3	$12K	Hold	2,000	–	–	﹤0.01%	6061
2017 Q2	$17K	Hold	2,000	–	–	﹤0.01%	5874
2017 Q1	$27K	Hold	2,000	–	–	﹤0.01%	5670
2016 Q4	$9K	Sell	2,000 -49,000	-96%	-$219K	﹤0.01%	5942
2016 Q3	$290K	Sell	51,000 -11,959	-19%	-$74.6K	﹤0.01%	3657
2016 Q2	$403K	Sell	62,959 -6,479	-9%	-$51.8K	﹤0.01%	3383
2016 Q1	$0	Sell	69,438 -1,885	-3%	-$16.2K	﹤0.01%	6374
2015 Q4	$713K	Buy	+71,323	New	+$725K	﹤0.01%	2911
2015 Q1	–	Sell	-6	Closed	–	–	7212
2014 Q4	$0	Hold	6	–	–	﹤0.01%	7524
2014 Q3	$0	Hold	6	–	–	﹤0.01%	7784
2014 Q2	$0	Hold	6	–	–	﹤0.01%	7768
2014 Q1	$0	Hold	6	–	–	﹤0.01%	7680
2013 Q4	$0	Hold	6	–	–	﹤0.01%	7643
2013 Q3	$0	Sell	6 -14	-70%	-$719	﹤0.01%	7558
2013 Q2	$1K	Buy	+20	New	+$1.06K	﹤0.01%	7600

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Barclays's PLX Position: Q1 2026 in Review

Barclays reduced its Protalix BioTherapeutics (PLX) stake by 87% in Q1 2026, selling an estimated $243K and leaving 14,822 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4454.

Barclays first reported a position in PLX in Q2 2013 and has held it in 40 quarters since. The position peaked at $713K in Q4 2015. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Barclays held 14,822 shares of Protalix BioTherapeutics worth $32.2K as of Q1 2026.
Barclays sold 98,027 Protalix BioTherapeutics shares in Q1 2026, an estimated $243K.
Protalix BioTherapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4454 holding.
Barclays first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 40 quarters since.
Barclays's Protalix BioTherapeutics position peaked at $713K in Q4 2015.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.